<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00555022</url>
  </required_header>
  <id_info>
    <org_study_id>AC5108696</org_study_id>
    <nct_id>NCT00555022</nct_id>
  </id_info>
  <brief_title>Effect of GSK1160724 In Healthy Volunteers</brief_title>
  <official_title>A Randomized Double-blind, Placebo-controlled, Crossover, Dose Escalation Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK1160724 and Tiotropium Bromide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK1160724 is a potent mAChR antagonist, which is being developed for treatment of chronic
      obstructive pulmonary disease (COPD)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2007</start_date>
  <completion_date type="Actual">April 7, 2008</completion_date>
  <primary_completion_date type="Actual">April 7, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events (AEs)</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study subjects, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal values for blood pressure</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Systolic and diastolic blood pressure will be measured in a semi-recumbent position after 5 minutes rest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal values for heart rate</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Heart rate will be measured in a semi-recumbent position after 5 minutes rest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal electrocardiogram (ECG) findings</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Triplicate 12-lead ECGs will be measured in a semi-recumbent position after 5 minutes rest at each time point using ECG machine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal findings after holter monitoring</measure>
    <time_frame>Up to 24 hour</time_frame>
    <description>Holter monitoring will be conducted at 24 hour.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Lung function will be measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced vital capacity (FVC)</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Lung function will be measured by FVC, defined as the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects having abnormal hematology laboratory parameters</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Hematology parameters will be assessed as a measure of safety.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal clinical chemistry parameters</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Clinical parameters will be assessed as a measure of safety.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal values for urinalysis</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Urinalysis will be performed as a measure of safety.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum value for resting heart rate over 0-4 hour</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Maximum value for heart rate over 0-4 hour will be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum value for resting blood pressure over 0-4 hour</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Maximum value for resting systolic and diastolic blood pressure over 0-4 hour will be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum value for resting ECG over 0-4 hour</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Maximum value for resting ECG over 0-4 hour will be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weighted mean of resting heart rate over 0-4 hour</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Weighted mean for resting heart rate over 0-4 hour will be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weighted mean of resting blood pressure over 0-4 hour</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Weighted mean for resting systolic and diastolic blood pressure over 0-4 hour will be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weighted mean of resting ECG over 0-4 hour</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Weighted mean for resting resting ECG over 0-4 hour will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of GSK1160724</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Plasma samples will be collected at the indicated time points to measure the concentration of GSK1160724.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of GSK1762245</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Plasma samples will be collected at the indicated time points to measure the concentration of the active metabolite GSK1762245.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentrations of GSK1160724</measure>
    <time_frame>0-2 hours, 2-8 hours, 8-12 hours and 12-24 hours</time_frame>
    <description>Urine samples will be collected at the indicated time points to measure the concentration of GSK1160724.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentrations of GSK1762245</measure>
    <time_frame>0-2 hours, 2-8 hours, 8-12 hours and 12-24 hours</time_frame>
    <description>Urine samples will be collected at the indicated time points to measure the concentration of the active metabolite GSK1762245.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of GSK1160724</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of GSK1762245</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of GSK1160724</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of GSK1762245</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to last observed plasma concentration (Tlast) of GSK1160724</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlast of GSK1762245</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve from time 0 to last time of quantifiable concentration (AUC [0-T]) of GSK1160724</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-T) of GSK1762245</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve from time 0 to infinity (AUC [0-infinity]) of GSK1160724</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-infinity) of GSK1762245</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The terminal phase elimination rate constant (Lambda z) of GSK1160724</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lambda z of GSK1762245</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Terminal phase half life (T1/2) of GSK1160724</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of GSK1762245</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours.12 hours, 16 hours, 24 hours, 48 hours Post-dose</time_frame>
    <description>Blood samples will be collected at the indicated time points for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial specific airway conductance (sGaw) response over 24 hours post-dose of GSK1160724 and tiotropium bromide</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>The sGaw response will be assessed by whole body plethysmograph at the indicated timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 over 24 hours post-dose of GSK1160724 and tiotropium bromide</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>The sGaw response will be assessed by whole body plethysmograph at the indicated timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC over 24 hours post-dose of GSK1160724 and tiotropium bromide</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>The sGaw response will be assessed by whole body plethysmograph at the indicated timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial sGaw measurements over 48 hours of GSK1160724 and tiotropium bromide</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>The sGaw is a measure of the change in specific airway conductance. It will be assessed by whole body plethysmograph at the indicated timepoints.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive one of the following treatment in cohort I and cohort II in five different treatment periods; Placebo, GSK1160724 (10 micrograms, 50 micrograms or 125 micrograms) and tiotropium bromide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1160724</intervention_name>
    <description>GSK1160724 will be available with dosing strengths of 10, 50 and 125 micrograms/blister for inhalation using the DISKUS inhaler.</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium bromide</intervention_name>
    <description>Tiotropium bromide capsules will be supplied with a dose of 18 micrograms administered via a HandiHaler device.</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo.</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects. Female subjects must be of non-child bearing
             potential.

          -  Aged between 18-55 years inclusive

          -  Non-smokers

          -  Normal spirometry

          -  A signed and dated written informed consent is obtained from the subject

          -  The subject is capable of giving informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form

          -  Available to complete the study

          -  The subject is greater than or equal to 50kg with a body mass index within the range
             19.0 to 29.9 kg/m2 inclusive

          -  Response to ipratropium bromide

        Exclusion Criteria:

          -  Any clinically relevant and important abnormality identified at the screening medical
             assessment (physical examination/medical history), clinical laboratory tests, or ECG
             (12-lead or Holter)

          -  A history of breathing problems

          -  A mean QTc(B) value &gt; 450ms, the QTc(B) of the 3 screening ECGs are not within 10% of
             the mean, a PR interval outside the range 90-210ms or an ECG that is not suitable for
             QT measurements at screening

          -  A history of elevated resting blood pressure or a mean blood pressure higher than
             140/90 mmHg at screening

          -  A mean heart rate outside the range 40-90 bpm inclusive at screening

          -  History of use of tobacco- or nicotine-containing products within 6 months of
             screening, and/or positive urine cotinine test results at screening

          -  Where participation in the study would result in donation of blood in excess of 500mL
             within a 56 day period at screening

          -  The subject is currently taking regular (or a course of) medication, whether
             prescribed or not, including herbal remedies such as St John's Wort etc.

        The subject has taken:

          -  prescription medications for 14 days prior to first dose of study drug, or

          -  Over-the-counter (OTC) medications/preparations (including herbal remedies, etc.)
             excluding simple analgesics for 48 hours prior to first dose of study drug,unless it
             is judged by the Investigator not to compromise the subject's safety or influence the
             outcome of the study.

          -  The subject has participated in a study with a new molecular entity or any other trial
             within a period of 3 months prior first dose of study drug

          -  The subject has tested positive for hepatitis C antibody (third generation enzyme
             immunoassay), hepatitis B surface antigen or HIV antibodies (if tested according to
             site SOP's) at screening.

          -  The subject has tested positive for drugs-of-abuse at screening

          -  The subject has tested positive for urine alcohol (including ethanol) at screening The
             detection of alcohol would not be an exclusion at screening but would need to be
             negative pre-dose and during the study

          -  The subject is unable to use the DISKUS™ and/or HandiHaler inhaler devices correctly
             at screening

          -  The subject has a suspected history of alcohol abuse within the six months previous to
             the screening visit

          -  The subject has a known allergy or hypersensitivity to magnesium stearate, milk
             protein or the excipient lactose monohydrate, iodine, ipratropium bromide, tiotropium
             bromide, atropine and/or any of its derivatives

          -  The subject has a significant clinical history of prostatic hypertrophy or narrow
             angle glaucoma

          -  The subject has received an allogeneic bone marrow transplant

          -  The subject has claustrophobia that may be aggravated by entering the whole body
             plethysmography cabinet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/AC5108696?search=study&amp;study_ids=AC5108696#rs</url>
    <description>Results for study AC5108696 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2007</study_first_submitted>
  <study_first_submitted_qc>November 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2007</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anticholinergic,</keyword>
  <keyword>FTIH,</keyword>
  <keyword>Muscarinic Receptor Antagonist,</keyword>
  <keyword>Plethysmography</keyword>
  <keyword>COPD,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

